Literature DB >> 12628862

Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.

Robert H Poe1, Michael C Kallay.   

Abstract

STUDY
OBJECTIVE: To evaluate experience using a therapeutic trial of proton-pump inhibitor therapy with or without a prokinetic agent in diagnosis and treatment of gastroesophageal reflux disease (GERD)-related cough.
DESIGN: A review of experience with 214 patients with cough of > or = 3 weeks referred over 3.5 years. An anatomic diagnostic protocol was used to identify and treat those with GERD-related cough.
SETTING: A pulmonary specialty practice affiliated with the University of Rochester School of Medicine and Dentistry. PATIENTS: One hundred eighty-three patients were identified with chronic cough and were included in the study. Thirty-one patients were disqualified because of abnormal chest radiographic findings, inadequate follow-up, or cough being not the primary complaint. Fifty-six patients were identified as having GERD-related cough.
INTERVENTIONS: A once-daily dose of a proton-pump inhibitor was prescribed. A prokinetic agent was added if esophageal dysfunction was suspected or response was inadequate. Those who did not respond underwent 24-h esophageal pH monitoring.
RESULTS: GERD was the single cause of cough in 24 patients (43%). Twenty-nine patients (52%) had GERD plus another cause, and 3 patients (5%) had GERD with more than two causes. Twenty-four patients (43%) had cough only, while 32 patients (57%) had other symptoms of GERD. Proton-pump therapy was successful in 42 patients (79%). Twenty-four patients responded to proton-pump inhibitor therapy, and 18 patients responded when metoclopramide or cisapride was added. The remaining two patients responded to a histamine type-2 blocker or cisapride alone. The cough was eliminated or markedly improved in 38 patients (86%) after 4 weeks and by 8 weeks in the remaining 6 patients. Six of the nonresponders had aspiration diagnosed by bronchoscopy. Four patients had fundoplication recommended, and two patients responded to alternative interventions.
CONCLUSIONS: Four to 6 weeks of a proton-pump inhibitor alone or in combination with a prokinetic agent successfully diagnoses and treats four of five patients with GERD-related cough. Twenty-four-hour esophageal pH monitoring will confirm the diagnosis in the others. These patients may be candidates for fundoplication. Nonresponders often aspirate as an additional aggravating factor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628862     DOI: 10.1378/chest.123.3.679

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

Review 1.  Cough: an unmet clinical need.

Authors:  Peter V Dicpinigaitis
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Hypopharyngeal pepsin and Sep70 as diagnostic markers of laryngopharyngeal reflux: preliminary study.

Authors:  Yoshihiro Komatsu; Lori A Kelly; Ali H Zaidi; Christina L Rotoloni; Juliann E Kosovec; Emily J Lloyd; Amina Waheed; Toshitaka Hoppo; Blair A Jobe
Journal:  Surg Endosc       Date:  2014-08-27       Impact factor: 4.584

Review 3.  Extra-laryngeal manifestations of gastro-oesophageal reflux.

Authors:  M De Benedetto; G Monaco; F Marra
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-10       Impact factor: 2.124

4.  Dental erosions and other extra-oesophageal symptoms of gastro-oesophageal reflux disease: Evidence, treatment response and areas of uncertainty.

Authors:  Ans Pauwels
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

5.  Airway reflux, cough and respiratory disease.

Authors:  Ian D Molyneux; Alyn H Morice
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

Review 6.  Extra-esophageal manifestations of GERD: who responds to GERD therapy?

Authors:  Rishi D Naik; Michael F Vaezi
Journal:  Curr Gastroenterol Rep       Date:  2013-04

Review 7.  Esophageal Impedance Monitoring: Clinical Pearls and Pitfalls.

Authors:  Karthik Ravi; David A Katzka
Journal:  Am J Gastroenterol       Date:  2016-06-21       Impact factor: 10.864

8.  New developments in extraesophageal reflux disease.

Authors:  Elif Saritas Yuksel; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09

9.  Salivary Pepsin Lacks Sensitivity as a Diagnostic Tool to Evaluate Extraesophageal Reflux Disease.

Authors:  Fei Dy; Janine Amirault; Paul D Mitchell; Rachel Rosen
Journal:  J Pediatr       Date:  2016-07-21       Impact factor: 4.406

10.  Pulmonary manifestations of gastroesophageal reflux disease.

Authors:  Gajanan S Gaude
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.